Spring brings more than just baby lambs

Article

A report presented at the annual meeting of the Association for Research in Vision and Ophthalmology (ARVO) held in May of this year, observed an increased number of uveitis cases at a New York clinic at the same time as there were peaks in tree pollen levels.

A report presented at the annual meeting of the Association for Research in Vision and Ophthalmology (ARVO) held in May of this year, observed an increased number of uveitis cases at a New York clinic at the same time as there were peaks in tree pollen levels.

Samir Tari, MD of the New York Eye and Ear Infirmary, USA conducted a retrospective study to investigate whether there was a seasonal pattern present in uveitis-related ophthalmic visits over a five-year period (2001-2005) at the centre. Over the five-year period, there were 21,440 cases of uveitis and these were divided into sub-categories: new cases, uveitis-related emergency visits, anterior uveitis-related visits (acute and chronic) and posterior uveitis-related visits.

Each year, the most frequent number of visits to the clinic for uveitis were in May, irrespective of type of visit. Overall there were an average of 391 uveitis-related visits to the centre in May, compared with 379.8 in April, 378.2 in June, 354.8 in July and 346 in November.

The researchers posited that there may be a link between pollen levels or even the increased daylight that occurs in the spring. Although tree pollen is not necessarily the culprit, it does suggest that it is an area worth looking into further.

Recent Videos
Thomas Aaberg, MD, gives an update on Neurotech Pharmaceuticals NT-501 device for the potential treatment of retinitis pigmentosa and age-related macular degeneration, including a projected PDUFA date from the FDA at the annual ASRS meeting in Stockholm, Sweden.
Sruthi Arepalli, MD, spoke with Modern Retina about her presentation, "Assessing retinal vascular changes in alzheimer disease with radiomics: A preliminary study of fundus photography" at the annual ASRS meeting in Stockholm, Sweden.
Nathan Steinle, MD, spoke with Modern Retina about the ongoing research on the durability of sozinibercept in combination therapy with anti-VEGF-A treatments at the annual ASRS meeting in Stockholm, Sweden.
Deepak Sambhara, MD, shared an overview of his paper-on-demand, which covered real-world safety and efficacy of aflibercept, 8 mg in the treatment of neovascular age-related macular degeneration at the annual ASRS meeting in Stockholm, Sweden.
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
© 2024 MJH Life Sciences

All rights reserved.